Roche's Strong Accusations Against U.S. Drug Review Practices Raise Concerns
Roche has leveled serious accusations against the U.S., claiming 'blackmail' tactics amid ongoing controversies surrounding drug reviews and skinny labels.
Editorial Staff
1 min read
Updated 4 days ago
On June 5, 2026, Roche publicly accused the U.S. government of employing 'blackmail' tactics in relation to drug review processes. This assertion comes amid growing scrutiny over regulatory practices.
The FDA has been urged by various stakeholders, including drugmakers and patient advocacy groups, to reconsider the National Priority Voucher drug review program initiated by former commissioner Marty Markary.
Concerns have been raised regarding the implications of recent rulings on skinny labels, which could significantly affect how drugs are marketed and reviewed in the U.S.